The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Size Is Forecasted For The Skyrizi Market By 2030 Based On Its 2026 Value?
The expansion during the historic period can be linked to a rise in the diagnosis of autoimmune conditions, the limitations inherent in conventional immunosuppressive treatments, the increasing uptake of biologics in both dermatology and gastroenterology, improved access to specialized medical care, and enhanced success rates in clinical trials.
The expansion projected for the forecast period can be linked to the increasing penetration into new inflammatory indications, greater investments in next-generation biologics, a rising patient inclination for convenient dosing regimens, a heightened healthcare focus on achieving durable remission, and the broadening of biologic treatment guidelines. Prominent trends within this period include the increased adoption of IL-23 targeted therapies, their growing application across numerous autoimmune conditions, a rising preference for biologics with long dosing intervals, the wider availability of self-administered injectable formats, and an intensified focus on long-term disease control.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20266&type=smp
What Primary Factors Are Fueling The Expansion Of The Skyrizi Market?
The anticipated expansion of the skyrizi market is linked to an increasing focus on personalized medicine. This medical strategy customizes treatments and healthcare plans for each patient, considering their unique attributes like genetics, surroundings, and habits, to deliver highly effective and accurate results. The growth in personalized medicine stems from progress in genomic technologies, deeper insights into molecular biology, wider access to precise diagnostic instruments, and a need for targeted treatments that enhance patient recovery with fewer adverse effects. Skyrizi contributes to personalized medicine by providing a specific biologic therapy that targets interleukin-23 (IL-23). This allows healthcare professionals to customize care for individuals suffering from moderate to severe autoimmune conditions, including psoriasis and ulcerative colitis, by considering their specific reactions and disease features, ultimately boosting effectiveness and reducing treatment side effects. For example, data from February 2024, released by the Personalized Medicine Coalition, a US-based hospital and health care organization, indicates that in 2023, the FDA sanctioned 16 novel personalized therapies for rare disease patients, which is an increase from six in 2022. Consequently, the expanding interest in personalized medicine propels the skyrizi market.
What Segment Types Are Included In The Skyrizi Market Analysis?
The skyrizi market covered in this report is segmented –
1) By Indication: Plaque Psoriasis, Crohn’s Disease, Ulcerative Colitis
2) By Formulation: Pre-Filled Syringes, Vials
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Which Trends Are Guiding The Development Of The Skyrizi Market?
Leading companies in the SKYRIZI market are channeling their efforts into developing innovative solutions, such as interleukin-23 (IL-23) inhibitor treatments, to satisfy the growing demand for targeted and highly efficacious therapies for autoimmune and chronic inflammatory illnesses. IL-23 inhibitors operate by specifically obstructing the p19 subunit of the IL-23 cytokine, which plays a pivotal role in driving inflammatory pathways. This directed approach offers enhanced effectiveness and safety compared to conventional broad-spectrum immunosuppressants. For example, in July 2024, AbbVie Inc., a US-based biopharmaceutical corporation, obtained European Commission approval for SKYRIZI (risankizumab) for treating adults with moderately to severely active ulcerative colitis who have either not responded to or are intolerant of standard or biologic therapies. SKYRIZI is a monoclonal antibody that selectively targets IL-23, offering a focused action mechanism that helps reduce inflammation and foster mucosal healing. The treatment protocol involves a 1,200 mg IV induction regimen, followed by 180 mg or 360 mg subcutaneous maintenance doses every eight weeks. Clinical evidence from the Phase 3 INSPIRE and COMMAND trials demonstrated robust outcomes, including significant mucosal healing and sustained remission, particularly in patients without prior biologic or JAK inhibitor exposure.
Who Are The Leading Firms Participating In The Skyrizi Market?
Major companies operating in the skyrizi market are AbbVie Inc.
Access The Complete Skyrizi Market Report:
https://www.thebusinessresearchcompany.com/report/skyrizi-global-market-report
Which Region Accounts For The Highest Share Of The Skyrizi Market?
North America was the largest region in the skyrizi market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the skyrizi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model